Scarica l'app Stockscreener
2.54
39.56%
0.72
Dopo l'orario di chiusura:
2.40
-0.14
-5.51%
Precedente Chiudi:
$1.82
Aprire:
$2.66
Volume 24 ore:
63.35M
Relative Volume:
57.49
Capitalizzazione di mercato:
$2.59M
Reddito:
-
Utile/perdita netta:
$-98.30M
Rapporto P/E:
-0.3523
EPS:
-7.2097
Flusso di cassa netto:
$-8.72M
1 W Prestazione:
+24.51%
1M Prestazione:
+13.39%
6M Prestazione:
-53.39%
1 anno Prestazione:
+189.29%
Intervallo 1D:
$2.3501
$3.37
Intervallo di 1 settimana:
$1.82
$3.37
Portata 52W:
$0.541
$30.30
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
Nome
Zyversa Therapeutics Inc
Settore
Industria
Telefono
908-370-5102
Indirizzo
217 W. MAIN STREET, SOMERVILLE
Zyversa Therapeutics Inc Borsa (ZVSA) Ultime notizie
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings - Benzinga
S&P 500 Gains 1%; Vimeo Shares Spike Higher - Benzinga
U.S. Stock market: Zoomcar Holdings (+192.21%), Avalon GloboCare (+56.73%), and Vimeo (+40.85%) experience significant gains during mid day trading - Business Upturn
U.S. Stock market: Zoomcar Holdings up 87.10%, Avalon GloboCare jumps 57.14%, Vimeo rises 44.07% among top gainers - Business Upturn
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga
ZyVersa reports progress on obesity inflammation treatment - Investing.com
Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - The Manila Times
ZyVersa reports progress on obesity inflammation treatment By Investing.com - Investing.com UK
ZyVersa Therapeutics Highlights Published Data - GlobeNewswire
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes - StockTitan
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
ZyVersa Therapeutics Highlights Review Article Supporting - GlobeNewswire
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs - StockTitan
ZyVersa reports obesity-linked brain inflammation study By Investing.com - Investing.com Canada
ZyVersa reports obesity-linked brain inflammation study - Investing.com
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases - GlobeNewswire
ZVSA stock touches 52-week low at $2.07 amid sharp annual decline - Investing.com Canada
ZVSAZyVersa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
ZyVersa advances obesity drug with key milestones ahead - Investing.com India
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months - The Manila Times
ZyVersa advances obesity drug with key milestones ahead By Investing.com - Investing.com UK
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter - GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured - GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to - The Bakersfield Californian
ZyVersa forms new SAB for obesity treatment advancement By Investing.com - Investing.com South Africa
ZyVersa forms new SAB for obesity treatment advancement - Investing.com India
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications - The Manila Times
ZyVersa Therapeutics Forms New Scientific Advisory Board to - GlobeNewswire
Proteinuria Therapeutics Strategic Business Report 2024: Innovations in Biomarker-Based Diagnosis Sustain Growth in Proteinuria Therapeutics MarketForecasts to 2030 - 24matins.uk
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
ZVSA stock touches 52-week low at $2.4 amid sharp annual decline - Investing.com UK
BTK Inhibitors Market to Observe Stunning Growth by 2034 | DelveInsight - PR Newswire UK
Thinking about buying stock in Visa Inc, Delta Air Lines, Barnes - GuruFocus.com
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Up 68.3% in July - Defense World
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa progresses with inflammation treatment IC 100 - Investing.com
ZyVersa progresses with inflammation treatment IC 100 By Investing.com - Investing.com UK
ZyVersa Therapeutics Announces Published Data Supporting - GlobeNewswire
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation - Yahoo Finance
Zyversa selects lead indication for ASC inhibitor IC-100 - BioWorld Online
ZyVersa Therapeutics Announces Published Data Demonstrating - GlobeNewswire
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults - StockTitan
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update - Defense World
ZyVersa sets obesity as focus for new drug IC 100 - Investing.com
ZyVersa sets obesity as focus for new drug IC 100 By Investing.com - Investing.com Nigeria
Zyversa Therapeutics names lead indication for inflammasome ASC inhibitor - BioWorld Online
ZyVersa Therapeutics Selects Obesity and Related Metabolic - GlobeNewswire
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100 - Yahoo Finance
Market Momentum: ZyVersa Therapeutics Inc (ZVSA) Registers a -10.80 Decrease, Closing at 3.88 - The Dwinnex
ZyVersa Therapeutics Inc (ZVSA) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Zyversa Therapeutics Inc Azioni (ZVSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):